CD274 and neoplasm: Across this 189 patient PD-L1 IHC cohort (overall 10 tumor types; 36.0% non-NSCLC), only 1 patient (0.5%) was MSI-H (who was also TMB-H), 25.9% were TMB-H, and 43.9% were IRS-H (Supplementary Table S6); median total follow-up in these patients was 10.9 months, with 106 (56.1%) progression events.